ISPOR 21ST ANNUAL INTERNATIONAL MEETING WORKSHOP EXAMINES METHODOLOGIES FOR EVALUATING GEOSPATIAL ACCESS

Published May 25, 2016
Washington, DC—May 25, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting Workshop 23—Methodologies for Evaluating Geospatial Access in Medication Use Studies—was held this afternoon in Washington, DC, USA. The discussion leaders for the session included:
  • Rajesh Balkrishnan, PhD, Professor, Public Health Sciences, University of Virginia School of Medicine, Charlottesville, VA, USA
  • Xi Tan, PhD, PharmD, Assistant Professor, Department of Pharmaceutical Systems and Policy, West Virginia University, School of Pharmacy, Morgantown, WV, USA
  • Joseph Donohoe, PhD, Informatics and Special Projects Lead, Mountain-Pacific Quality Health, Helena, Helena, MT, USA
Large database studies that analyze health outcomes for medications often find significant variation in utilization due to differential geographical access. Discussion leaders reviewed newer measures and techniques of geospatial access to medications, including two-step floating catchment area (2SFCA), geographic hot spot analyses, and geographic weighted regression in evaluating the access and utilization of adjuvant endocrine therapy in breast cancer survivors residing in Appalachia, a poor and underserved region in the US with significant geospatial access issues. Presentations and slide decks from the ISPOR 21st Annual International meeting can be found here. Interested parties can follow news and developments from the meeting on social media using the hashtag #ISPORDC.

###

Related Stories

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Europe 2025 Plenaries and Speakers Announced

Oct 13, 2025

ISPOR announced details for its ISPOR Europe 2025. The conference is the leading global conference in Europe for health economics and outcomes research (HEOR) and is scheduled for 9-12 November in Glasglow, Scotland, UK with the theme, “Powering Value and Access Through Patient-Centered Collaboration.”
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×